Myriad Genetics Inc.
10/03/2025 | Press release | Distributed by Public on 10/03/2025 14:27
Management Change/Compensation (Form 8-K)
ITEM 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
Departure of Natalie Munk as Principal Accounting Officer
On September 29, 2025, Natalie Munk, the Senior Vice President, Chief Accounting Officer and principal accounting officer of Myriad Genetics, Inc.'s (the "Company"), provided notice of her resignation from the Company, effective on October 24, 2025. Ms. Munk's departure is not a result of any disagreement between Ms. Munk and the Company on any matter relating to the Company's operations, policies or practices.
Appointment of Ben R. Wheeler as as Principal Accounting Officer
In connection with Ms. Munk's departure, on October 1, 2025, the Board of Directors of the Company (the "Board") designated Benjamin R. Wheeler, the Company's Chief Financial Officer and principal financial officer, to also serve as the Company's principal accounting officer, effective upon Ms. Munk's departure from the Company.
Mr. Wheeler, 42, has served as the Company's Chief Financial Officer since August 2025. Prior to that, Mr. Wheeler served in various roles of increasing responsibility at the Company over the past thirteen years, including Senior Vice President, Chief Financial Officer, Operations, since June 2022, and Senior Vice President, Finance and Treasury, since July 2020. Mr. Wheeler has also served at the Company as Senior Vice President, Accounting, from June 2018 to July 2020, Vice President, Corporate Controller, from December 2014 to June 2018, and in other controllership positions from December 2011 to December 2014. Before joining the Company, Mr. Wheeler served as an auditor for Ernst & Young. Mr. Wheeler holds both master's and bachelor's degrees in accounting from Brigham Young University and is a Certified Public Accountant.
Mr. Wheeler did not receive any additional compensation upon his designation as principal accounting officer of the Company. There are no arrangements or understandings between Mr. Wheeler and any other person pursuant to which he was designated as the Company's principal accounting officer. Additionally, Mr. Wheeler is not a party to any transaction that would require disclosure under Item 404(a) of Regulation S-K, and he does not have any family relationships that are required to be disclosed pursuant to Item 401(d) of Regulation S-K.
Myriad Genetics Inc. published this content on October 03, 2025, and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT) on October 03, 2025 at 20:27 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]